In conclusion, although SGLT2 is expressed in the testis and contrary to animal data, the use of a highly selective SGLT2 inhibitor, empagliflozin, does not affect serum testosterone or inhibin levels in men without diabetes. This evidence concerns the gene SLC5A2 and diabetes mellitus.